Drug Trial Radar · NCT05032144
The Safety and Tolerability of STSA-1002 Following Intravenous Infusion in Healthy Subjects
Last checked: Nov 19, 2026Latest source record: Apr 11, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
40
Actual
Start
Sep 28, 2021
Primary completion
Mar 31, 2022
Study completion Mar 31, 2022
Sponsor
- Lead sponsor
- Staidson (Beijing) Biopharmaceuticals Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Sep 2, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
A randomized,double-blind,placebo-controlled,single-ascending dose phase Ⅰa study to evaluate the safety,tolerability,pharmacokinetics and pharmacodynamics of STSA-1002 following intravenous infusion in healthy subjects
Conditions
- Healthy
Interventions
STSA-1002 injectionDrug
Intravenous injection
PlaceboDrug
Intravenous injection
STSA-1002 injectionDrug
Intravenous injection
PlaceboDrug
Intravenous injection
STSA-1002 injectionDrug
Intravenous injection
PlaceboDrug
Intravenous injection
STSA-1002 injectionDrug
Intravenous injection
PlaceboDrug
Intravenous injection
STSA-1002 injectionDrug
Intravenous injection
PlaceboDrug
Intravenous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Adverse Events, Clinically Significant Laboratory Abnormalities,Clinically Significant Electrocardiogram Abnormalities, Clinically Significant Vital Signs Abnormalities And Clinically Significant Physical Examination AbnormalitiesTime frame: Day 1 through Day 51
- Maximum plasma concentration(Cmax)Time frame: Up to 1200 hours postdose
- Area under the plasma concentration-time curve from time 0 to the collection time point of the last measurable concentration(AUC 0-t)Time frame: Up to 1200 hours postdose
- Area under the plasma concentration-time curve from time 0 to infinity(AUC0-∞)Time frame: Up to 1200 hours postdose
- Time of maximum concentration(Tmax)Time frame: Up to 1200 hours postdose
- Elimination half-life(t1/2)Time frame: Up to 1200 hours postdose
- Elimination rate constant of plasma drug concentration in terminal phase(λz)Time frame: Up to 1200 hours postdose
- Last measurable concentration(Clast)Time frame: Up to 1200 hours postdose
- Mean residence time(MRT)Time frame: Up to 1200 hours postdose
- Clearance(CL)Time frame: Up to 1200 hours postdose
- Apparent volume of distribution(Vz)Time frame: Up to 1200 hours postdose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
AltaSciences Clinical Kansas, Inc
Overland Park, Kansas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.